Fact.MR, A Market Research and Competitive Intelligence Provider, has conducted a comprehensive analysis on the pulmonary arterial hypertension market, which is expected to rise at a CAGR of 5.4% over the forecast period.
North America Is Projected To Account For 35% Share Of The Pulmonary Arterial Hypertension Market In 2022.
“Governments from all over the world are providing funds for the research and provision of high-quality treatments for pulmonary arterial hypertension; this key factor will stimulate market expansion over the coming years,” says a Fact.MR analyst
Fact.MR, A Market Research and Competitive Intelligence Provider, has conducted a comprehensive analysis on the pulmonary arterial hypertension (PAH) market, which is expected to rise at a CAGR of 5.4% over the forecast period (2021 to 2028).
Pulmonary arterial hypertension is a severe pulmonary arterial hypertension illness. With the rising incidences of heart problems, which lead to pulmonary arterial hypertension, the market is predicted to develop significantly over the forecast period.
Recent advances in the treatment of pulmonary arterial hypertension have resulted in improved clinical results, including a lower death rate and a higher quality of life. The market is expected to be driven by an increase in the number of drug pipelines and rising healthcare spending in various areas of the world. Demand will also increase as the senior population grows and the global prevalence of hypertension rises.
In addition, ongoing research targeted at producing highly specific and effective therapeutics for PAH is focusing on developing integrative medicines that combine traditional and experimental substances.
For more insights into the Market, Get A Sample of this Report!
https://www.factmr.com/connectus/sample?flag=S&rep_id=7234
Key Takeaways from Market Study
- Global pulmonary arterial hypertension market to reach a valuation of US$ 4.44 Bn by 2028.
- Market in North America holds a share of 35%.
- Demand for endothelin receptor antagonists (ERAs) is expected to increase at a 5% CAGR over the forecast period.
Winning Strategy
Various strategic efforts are being implemented by industry participants in order to expand their market share. Product development and launches, distribution network expansion, partnerships, and mergers and acquisitions are all examples of this. To obtain a competitive advantage and strengthen their industrial presence, companies invest extensively in the development and sale of highly innovative products.
Many pharmaceutical companies are attempting to enter the PAH market by releasing generic versions of pulmonary arterial hypertension medications. In the next years, this is expected to boost competition.
For instance,
- In November 2020, Viatris Inc. was formed by combining Mylan N.V. and Pfizer Inc.'s Upjohn Business. Viatris has a large portfolio of biosimilars, branded and sophisticated generics, and over-the-counter pharmaceuticals, including Revatio, a PAH medication.
Key Segments Covered in Pulmonary Arterial Hypertension Industry Research
Pulmonary Arterial Hypertension Market by Drug Class:
-
- Prostacyclin & Prostacyclin Analogs
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
Pulmonary Arterial Hypertension Market by Pipeline Analysis:
-
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
Pulmonary Arterial Hypertension Market by Region:
-
- North America Pulmonary Arterial Hypertension Market
- Europe Pulmonary Arterial Hypertension Market
- Asia Pacific Pulmonary Arterial Hypertension Market
- Latin America Pulmonary Arterial Hypertension Market
- Middle East & Africa Pulmonary Arterial Hypertension Market
Get Customization on this Report for Specific Research Solutions
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7234
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global pulmonary arterial hypertension market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2028.
The study divulges essential insights on the market on the basis of drug class (prostacyclin & prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators), by pipeline analysis (early-stage drug candidates (phase I & phase II) and late-stage drug candidates (phase III & registration Phase)), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
Fact.MR’s Domain Knowledge in Healthcare
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
Check out more studies related to Healthcare Industry, conducted by Fact.MR:
Intrapartum Monitoring Devices Market Outlook (2022-2032) - The global intrapartum monitoring devices market was valued at US$ 2.2 Billion in 2021, and is projected to register a Y-o-Y increase of 4.5% in 2022 to be valued at US$ 2.3 Billion.
Europe Patient Positioning System Market Outlook (2022-2032) - The Europe patient positioning system market is currently valued at US$ 287.5 million and is projected to register 4.5% CAGR through 2032. As such, patient positioning system sales in Europe are set to provide US$ 161.1 million of absolute dollar opportunity over the next ten years.
Global Mobile Imaging Services Market Outlook - The mobile imaging services market is predicted to grow at a steady CAGR of 3.9% during the projected period of 2022 to 2032. The mobile imaging services market share is estimated to be worth more than US$ 2.7 Billion by 2032, increasing from US$ 1.8 Billion in 2021.
U.S. Patient Positioning System Market Outlook (2022-2032) - Patient positioning system sales in the United States are estimated to cross a market valuation of US$ 324.8 million by the end of 2032.
Global Mixed Mode Chromatography Resin Market Outlook - The mixed mode chromatography resin market is predicted to grow at an impressive CAGR of 15.7% during the forecast period covering 2022 to 2032.
Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook (2022-2032) - The global idiopathic thrombocytopenic purpura therapeutics market was valued at US$ 587.0 Million in 2021, and is projected to be valued at US$ 620.5 Million in 2022.
Global Medical Nonwoven Disposables Market Outlook 2022 to 2032 - The medical nonwoven disposables market is predicted to grow at a moderate CAGR of 3.5% during the forecast period covering 2022 to 2032.
Global Contrast Media Injectors Market Outlook (2022-2032) - With a Y-o-Y growth rate of 7.1%, the global contrast media injectors market is estimated at US$ 1.5 Billion in 2022, as against US$ 1.4 Billion in 2021.
Global Fixed and Mobile C-Arms Market Outlook - The fixed and mobile c-arms market is predicted to grow at a steady CAGR of 4.3% during the projected period of 2022 to 2032.
Collateral Ligament Stabilizer System Market Snapshot -The global collateral ligament stabilizer system market was valued at US$ 1.8 Billion in 2021, and is projected to register a Y-o-Y increase of 6.6% in 2022 to be valued at US$ 1.9 Billion.
Facial Implant Market Outlook (2022-2032) - The global facial implant market was valued at US$ 2.7 Billion in 2022, and is expected to rise at a 7.7% value CAGR, likely to reach US$ 5.6 Billion by the end of the 2022-2032 forecast period.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
Email: sales@factmr.com
Tel: +1 (628) 251-158